Skip to main content
Type:Studiedocumentatie
Ziektebeelden:,
Leeftijd:≥ 18 jaar
Fase:Fase 3
Lijn:1e lijn
Status:Gesloten
Locatie:Amsterdam UMC
Volledige titel A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by oneyear maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
Documenten

 

Samenvatting met in- en exclusiecriteria

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy – Full Text View – ClinicalTrials.gov

Veiligheidsinformatie

Niet geregistreerde geneesmiddelen

Gilteritinib en Midostaurin

Geregistreerde geneesmiddelen

zie farmacotherapeutisch kompas of neem contact op met apotheek

NB
Principal investigator Amsterdam UMC Marjolein Donker, Bart Biemond
Principal investigator elders